Wednesday, November 7, 2018 – Friday, November 9, 2018

New York Marriott Marquis

1535 Broadway 

New York, NY 10036

(800) 843-4898

Rapid changes continue to occur in the management of solid and hematologic malignancies. Just this past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to enter the field. Improved outcomes are achievable across multiple lines of care with the application of optimized testing approaches, locoregional and systemic therapies, targeted therapies, immunotherapies, and multimodal strategies. Critical knowledge and competence gaps among practitioners must be addressed to ensure that these approaches are effectively and safely integrated into practice. Each year, the Chemotherapy Foundation Symposium^® (CFS^®), brings together more than 2000 healthcare professionals for 3 days, with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for routine and the most challenging clinical scenarios. At the 36th Annual CFS^®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics, offering oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer.

• Incorporate the latest clinical data into your practice
• Challenge the experts with your most difficult cases
• Network with the top minds in oncology
• 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource^®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource^®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 26.75 Contact Hours.

ACCREDITATION/CREDIT DESIGNATION FOR PHARMACISTS

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is approved for a maximum of 22.75 contact hours under the ACPE universal activity numbers:

November 7, 2018, Conference Day 1 – 0290-9999-18-099-L01-P (7.75 contact hours)

November 8, 2018, Conference Day 2 – 0290-9999-18-100-L01-P (7.0 contact hours)

November 9, 2018, Conference Day 3 – 0290-9999-18-101-L01-P (8.0 contact hours)

The activity is available for continuing education (CE) credit t

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Upon successful completion of this activity, you should be better prepared to:

• Determine the most appropriate testing strategies to identify molecular marker and treatment targets while stratifying risk to inform clinical decision-making in cancer management
• Describe key practice-changing clinical trial results that inform appropriate diagnostic and treatment approaches for patients with hematologic malignancies and solid tumors
• Identify evidence-based immunotherapeutic, chemotherapeutic, and targeted treatment strategies to optimize clinical outcomes
• Delineate implementation strategies for multidisciplinary teams to anticipate and proactively manage treatment-related toxicities
• Review and apply practice-changing evidence presented at major conferences and apply these findings to optimize the care of patients with cancer

• Immunotherapies and Their Latest Applications in Cancer
• Harnessing the Latest Technologies, Biomarkers, and Tests to Optimize Clinical Decision Making
• Pan-Tumor Testing to Guide Treatment Planning
• Expanded Applications of Precision Medicine
• Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy
• Chemotherapy Versus Modern Agents: How to Get the Most Out of Available Therapies
• Focused Update on Rare Hematologic Malignancies: Waldenström Macroglobulinemia and Blastic Plasmacytoid Dendritic Cell Neoplasm
• Does Chemotherapy Improve Outcomes in Early-Stage High-Risk Uterine Cancer?
• State-of-the-Art Care for Patients With Melanoma: Sequencing, Triplet Combinations, Adjuvant Therapy, and Immunotherapy Selection
• Evolving Treatment Paradigms in Lung Cancer: New Agents, New Indications, New Assays
• Targeted and immunotherapeutic strategies for RCC and Bladder Cancer
• PARP Inhibitor-Based Therapy for Breast and Gynecologic Cancers
• Fertility Preservation in Premenopausal Women With Breast Cancer
• Evidence-Based Management Updates Across All Breast Cancer Subtypes
• Who Should Receive Extended Adjuvant Hormone Therapy for Breast Cancer?
• Improving Outcomes Through Optimized Adverse Event Management
• New Agents, New Opportunities, and New Clinical Questions in Gastrointestinal Cancers
• Updates in Glioblastoma Multiforme; Head, Neck, and Thyroid Cancers; and Sarcoma
• 2018 Special Focus: Patient-Centered Care and Oncology Practice: CINV, Pain Management, Neutropenia, Direct-to-Consumer Testing, and Next-Generation Sequencing
• Back by Popular Demand: Nursing and How I Do It tracks and Medical Crossfire® debates
• And Much More!